{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:54:17Z","timestamp":1776092057226,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005681","name":"Genesis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.neuroscience.2020.01.037","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T11:16:07Z","timestamp":1581160567000},"page":"34-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Elevated Serum \u03b1-Synuclein Levels in Huntington\u2019s Disease Patients"],"prefix":"10.1016","volume":"431","author":[{"given":"Marianthi","family":"Breza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Emmanouilidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouela","family":"Leandrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrisoula","family":"Kartanou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Bougea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Panas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Stefanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-5717","authenticated-orcid":false,"given":"Georgia","family":"Karadima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5702-9953","authenticated-orcid":false,"given":"Kostas","family":"Vekrellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Koutsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2020.01.037_b0005","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bpa.12370","article-title":"Alpha-synuclein as a biomarker for Parkinson\u2019s disease","volume":"26","author":"Atik","year":"2016","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener Dis"},{"issue":"1","key":"10.1016\/j.neuroscience.2020.01.037_b0015","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1016\/j.neuroscience.2020.01.037_b0020","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00415-018-8992-7","article-title":"Neuropsychiatric symptoms and \u03b1-Synuclein profile of patients with Parkinson\u2019s disease dementia, dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"265","author":"Bougea","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0025","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"40","author":"Bougea","year":"2019","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0304-3940(00)01247-7","article-title":"Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington\u2019s disease patients and transgenic mouse models","volume":"289","author":"Charles","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/hmg\/ddr477","article-title":"\u03b1-Synuclein levels modulate Huntington\u2019s disease in mice","volume":"21","author":"Corrochano","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0022225","article-title":"Assessment of \u03b1-synuclein secretion in mouse and human brain parenchyma","volume":"6","author":"Emmanouilidou","year":"2011","journal-title":"PLoS One"},{"issue":"Pt 3","key":"10.1016\/j.neuroscience.2020.01.037_b0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/bj3460577","article-title":"Alpha-synuclein overexpression promotes aggregation of mutant huntingtin","volume":"346","author":"Furlong","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.febslet.2011.11.019","article-title":"\u03b1-Synuclein modifies huntingtin aggregation in living cells","volume":"586","author":"Herrera","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0055","doi-asserted-by":"crossref","unstructured":"Jimenez-sanchez M, Licitra F, Underwood BR, Rubinsztein DC (2017). Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies.","DOI":"10.1101\/cshperspect.a024240"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0060","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbrc.2009.07.039","article-title":"Polyglutamine expansion in huntingtin increases its insertion into lipid bilayers","volume":"387","author":"Kegel","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10.1016\/j.neuroscience.2020.01.037_b0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrneurol.2015.197","article-title":"Pathogenesis of Parkinson disease\u2014the gut\u2013brain axis and environmental factors","volume":"11","author":"Klingelhoefer","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0123444","article-title":"Alpha-synuclein levels in blood plasma decline with healthy aging","volume":"10","author":"Koehler","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0075","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","article-title":"The plasma alpha-synuclein levels in patients with Parkinson\u2019s disease and multiple system atrophy","volume":"113","author":"Lee","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2016-314857","article-title":"Plasma \u03b1-synuclein predicts cognitive decline in Parkinson\u2019s disease","author":"Lin","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.410080408","article-title":"Membrane studies in Huntington\u2019s disease: Steady-state fluorescence studies of intact erythrocytes","volume":"8","author":"Pettegrew","year":"1980","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/mds.22928","article-title":"Plasma a-synuclein in patients with Parkinson\u2019s disease with and without treatment","volume":"25","author":"Duran","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neuroscience.2020.01.037_b0095","article-title":"Alteration in fluidity of cell plasma membrane in huntington disease revealed by spectral phasor analysis","volume":"8","author":"Sameni","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/BMM.14.105","article-title":"The utility of \u03b1-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature","volume":"10","author":"Simonsen","year":"2016","journal-title":"Biomark Med"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease","volume":"135","author":"St-Amour","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a009399","article-title":"Alpha-synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0115","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10048-016-0478-0","article-title":"Up-regulation of SNCA gene expression: implications to synucleinopathies","volume":"17","author":"Tagliafierro","year":"2016","journal-title":"Neurogenetics"},{"key":"10.1016\/j.neuroscience.2020.01.037_b0125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/hmg\/ddr507","article-title":"\u03b1-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington\u2019s disease","volume":"21","author":"Tom\u00e1s-Zapico","year":"2012","journal-title":"Hum Mol Genet"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452220300671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452220300671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T15:54:37Z","timestamp":1759679677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452220300671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":25,"alternative-id":["S0306452220300671"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2020.01.037","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated Serum \u03b1-Synuclein Levels in Huntington\u2019s Disease Patients","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2020.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IBRO. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}